Abstract
Psoriasis is a life-long disease that requires long-term treatment. The long-term use of conventional systemic treatments is limited mostly by poor tolerability and cumulative toxicity. Psoriasis significantly impairs the quality of life of patients .In contrast, the long-term use of biologics is more advisable, because of better tolerability and safety, although their cost hinders their clinical usage Evidence suggests that PASI 100 (i.e., complete clearance of psoriasis) may be achievable for many patients with moderate-to severe psoriasis using biologics in development brodalumab and ixekizumab or secukinumab that inhibit interleukin (IL)-17. Keywords: Psoriasis, Inflammation, TCell Activation biologics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of Geriatric Education and Medical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
